Herold Advisors Inc. Sells 1,000 Shares of BioNTech SE (NASDAQ:BNTX)

Herold Advisors Inc. decreased its stake in shares of BioNTech SE (NASDAQ:BNTXFree Report) by 33.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,000 shares of the company’s stock after selling 1,000 shares during the quarter. Herold Advisors Inc.’s holdings in BioNTech were worth $217,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Financial Gravity Asset Management Inc. acquired a new stake in shares of BioNTech in the second quarter worth $123,000. Eagle Bay Advisors LLC acquired a new stake in shares of BioNTech in the second quarter worth $33,000. State of Wyoming acquired a new stake in shares of BioNTech in the second quarter worth $26,000. EverSource Wealth Advisors LLC increased its stake in shares of BioNTech by 61.6% in the second quarter. EverSource Wealth Advisors LLC now owns 299 shares of the company’s stock worth $32,000 after acquiring an additional 114 shares during the period. Finally, Resurgent Financial Advisors LLC acquired a new stake in BioNTech during the fourth quarter valued at $47,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Price Performance

Shares of BNTX stock opened at $93.14 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.38 and a quick ratio of 10.14. The firm’s 50-day moving average is $101.43 and its two-hundred day moving average is $104.41. BioNTech SE has a 12 month low of $88.00 and a 12 month high of $147.66. The company has a market capitalization of $22.14 billion, a PE ratio of 8.08 and a beta of 0.27.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BNTX. HSBC lowered shares of BioNTech from a “buy” rating to a “hold” rating and dropped their price target for the company from $124.00 to $111.00 in a research report on Monday, October 16th. Oppenheimer began coverage on shares of BioNTech in a research report on Friday, January 5th. They set a “market perform” rating on the stock. HC Wainwright dropped their price target on shares of BioNTech from $133.00 to $107.00 and set a “buy” rating on the stock in a research report on Tuesday, January 23rd. Morgan Stanley increased their price objective on shares of BioNTech from $110.00 to $111.00 and gave the company an “equal weight” rating in a report on Wednesday, November 8th. Finally, JPMorgan Chase & Co. downgraded shares of BioNTech from a “neutral” rating to an “underweight” rating and decreased their price objective for the company from $106.00 to $99.00 in a report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $149.46.

Check Out Our Latest Stock Report on BioNTech

BioNTech Profile

(Free Report)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

Featured Articles

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE (NASDAQ:BNTXFree Report).

Institutional Ownership by Quarter for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.